ClinicalTrials.gg
RecruitingNCT05152368Updated Oct 20, 2026

Safety of Cultured Allogeneic Adult Umbilical Cordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia

A Phase 1 interventional study of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes in Peripheral Neuropathy and Trigeminal Neuralgia, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Updated Oct 20, 2026First sites in Greece and United StatesNo longer in Antigua and Barbuda+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.

Planned enrollment
117th of 157
20 · median 43
Started
2022
with 10 others
Phase 1
6 of 191
2 open now
Primary completion
2028-01
later than 32 of 46 live
Registered
149th of 191
by date

Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 117th largest by planned enrollment of the 157 interventional ones that give a count, is one of 11 that started in 2022, is one of 6 in phase 1, reaches primary completion later than 32 of the 46 other live ones, and was the 149th registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Peripheral Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.

Read the detailed description

This patient funded trial aims to study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell (MSCs) exosomes for the treatment of Trigeminal Neuralgia. Patients will receive an intranasal instillation of MSCs exosomes. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

03

Conditions studied

  • Peripheral Neuropathy
  • Trigeminal Neuralgia

Keywords

  • Peripheral Neuropathy
  • Trigeminal Neuralgia
  • stem cell treatment
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Trigeminal Neuralgia or Peripheral Neuropathy
  • Understanding and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • Abnormalities on pre-treatment laboratory evaluation
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
  • Continued drug abuse
  • Pre-menopausal women not using
  • Previous organ transplant
  • to sulfur
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Intranasal installation of exosomes

    Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

Interventions

  • Biologicalcultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

    cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes

06

What researchers measure

Primary outcomes

  1. Safety (adverse events)

    Clinical monitoring of possible adverse events or complications

    Time frame: Four year follow-up

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2022 (actual). Primary completion is estimated for Jan 2028, 64 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jan 2026 → Jan 2028 and completion Jan 2026 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 9, 2021
StartActual
Sep 9, 2022
Primary completionEst.
Jan 2028was Jan 2026
CompletionEst.
Jan 2028was Jan 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed — first sites in Greece and United States; no longer in Antigua and Barbuda
Show 2 added (1 United States, 1 Greece)
  • Prodromos Stem Cell Institute · Naples, United States
  • Prodromos Stem Cell Institute · Athens, Greece
Show 1 removed
  • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
Oct 20, 2026
Primary completion
Jan 2026→Jan 2028
Oct 20, 2026
Study completion
Jan 2026→Jan 2028
Oct 20, 2026
Interventions
Added Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes; removed Biological: AlloEx. Arm changed Treatment Group (AlloEx)→Treatment Group
Oct 20, 2026
Title
Safety of Cultured Allogeneic Adult Umbilical CordCordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites added, 1 site removed — first sites in Greece and United States; no longer in Antigua and Barbuda
    Show 2 added (1 United States, 1 Greece)
    • Prodromos Stem Cell Institute · Naples, United States
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 1 removed
    • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
    Primary completion Jan 2026→Jan 2028
    Study completion Jan 2026→Jan 2028
    Interventions Added Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes; removed Biological: AlloEx. Arm changed Treatment Group (AlloEx)→Treatment Group
    Title Safety of Cultured Allogeneic Adult Umbilical CordCordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia
    + 4 other changes: verification date, description, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05152368
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Sep 9, 2022
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Chadwick Prodromos, MD
principal investigator · The Foundation for Orthopaedics and Regenerative Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion